{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:11:15Z","timestamp":1793319075815,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100017691","name":"Guangxi Key Research and Development Program","doi-asserted-by":"publisher","award":["2022SK2029"],"award-info":[{"award-number":["2022SK2029"]}],"id":[{"id":"10.13039\/501100017691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81800271"],"award-info":[{"award-number":["81800271"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.ahj.2023.05.019","type":"journal-article","created":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T01:22:54Z","timestamp":1685841774000},"page":"10-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Initial treatment with a single capsule containing half-dose quadruple therapy vs standard-dose dual therapy in hypertensive patients (QUADUAL): Study protocol for a randomized, blinded, crossover trial"],"prefix":"10.1016","volume":"264","author":[{"given":"Xiexiong","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingle","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongshu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaogang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8369-9694","authenticated-orcid":false,"given":"Weihong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2023.05.019_bib0001","first-page":"182","article-title":"2018 Chinese Guidelines for prevention and treatment of hypertension-a report of the revision committee of chinese guidelines for prevention and treatment of hypertension","volume":"16","year":"2019","journal-title":"J Geriatr Cardiol"},{"key":"10.1016\/j.ahj.2023.05.019_bib0002","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 International Society of Hypertension Global Hypertension Practice Guidelines","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2023.05.019_bib0003","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","article-title":"Risk factors collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019","volume":"396","author":"G","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2023.05.019_bib0004","first-page":"521","article-title":"Report on cardiovascular health and diseases burden in China: an updated summary of 2020","volume":"36","year":"2021","journal-title":"Chinese Circulation Journal"},{"key":"10.1016\/j.ahj.2023.05.019_bib0005","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1016\/S0140-6736(17)32478-9","article-title":"Prevalence, awareness, treatment, and control of hypertension in China: data from 1.7 million adults in a population-based screening study (China PEACE Million Persons Project)","volume":"390","author":"Lu","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2023.05.019_bib0006","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(19)31293-0","article-title":"Blood pressure control: a challenge to global health systems","volume":"394","author":"Chow","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2023.05.019_bib0007","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1001\/jama.2013.184182","article-title":"Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries","volume":"310","author":"Chow","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2023.05.019_bib0008","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1161\/HYPERTENSIONAHA.120.15462","article-title":"Treatment patterns and blood pressure control with initiation of combination versus monotherapy antihypertensive regimens","volume":"77","author":"An","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2023.05.019_bib0009","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/HJH.0000000000001181","article-title":"Blood pressure control in hypertension. Pros and cons of available treatment strategies","volume":"35","author":"Mancia","year":"2017","journal-title":"J Hypertens"},{"key":"10.1016\/j.ahj.2023.05.019_bib0010","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/HJH.0000000000000409","article-title":"Comparison of single-pill strategies first line in hypertension: perindopril\/amlodipine versus valsartan\/amlodipine","volume":"33","author":"Mancia","year":"2015","journal-title":"J Hypertens"},{"key":"10.1016\/j.ahj.2023.05.019_bib0011","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jash.2010.03.001","article-title":"Combination therapy in hypertension","volume":"4","author":"Gradman","year":"2010","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.ahj.2023.05.019_bib0012","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.amjhyper.2007.02.017","article-title":"Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy","volume":"20","author":"Weir","year":"2007","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ahj.2023.05.019_bib0013","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0140-6736(10)62003-X","article-title":"Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial","volume":"377","author":"Brown","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2023.05.019_bib0014","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(04)16456-8","article-title":"Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial","volume":"363","author":"Weber","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2023.05.019_bib0015","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1161\/HYPERTENSIONAHA.112.201566","article-title":"Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study","volume":"61","author":"Gradman","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2023.05.019_bib0016","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1161\/HYPERTENSIONAHA.111.177592","article-title":"Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice","volume":"58","author":"Corrao","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2023.05.019_bib0017","first-page":"881","article-title":"Benefit of initial dual-therapy on stroke prevention in Chinese hypertensive patients: a real world cohort study","volume":"7","author":"Yu","year":"2015","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ahj.2023.05.019_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001860","article-title":"The cost-effectiveness of low-cost essential antihypertensive medicines for hypertension control in China: a modelling study","volume":"12","author":"Gu","year":"2015","journal-title":"PLoS Med"},{"key":"10.1016\/j.ahj.2023.05.019_bib0019","series-title":"Internal Medicines: People\u2019s","author":"Junbo","year":"2018"},{"key":"10.1016\/j.ahj.2023.05.019_bib0020","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2174\/15748847113086660075","article-title":"Management of hypertension-journey from single drug therapy to multitargeted ligand therapy: a clinical overview","volume":"10","author":"Naik","year":"2015","journal-title":"Curr Clin Pharmacol"},{"key":"10.1016\/j.ahj.2023.05.019_bib0021","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1161\/CIRCRESAHA.119.314724","article-title":"Implications of guidelines for hypertension management in Europe","volume":"124","author":"Volpe","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2023.05.019_bib0022","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1136\/bmj.326.7404.1427","article-title":"Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials","volume":"326","author":"Law","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.ahj.2023.05.019_bib0023","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.jacc.2017.11.005","volume":"71","author":"Whelton","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2023.05.019_bib0024","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2023.05.019_bib0025","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2023.05.019_bib0026","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1097\/HJH.0000000000002072","article-title":"Latin American Consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome","volume":"37","author":"Lopez-Jaramillo","year":"2019","journal-title":"J Hypertens"},{"key":"10.1016\/j.ahj.2023.05.019_bib0027","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","article-title":"The Japanese Society of Hypertension Guidelines for the management of hypertension (JSH 2019)","volume":"42","author":"Umemura","year":"2019","journal-title":"Hypertens Res"},{"key":"10.1016\/j.ahj.2023.05.019_bib0028","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1097\/HJH.0000000000002453","article-title":"2020 International Society of Hypertension global hypertension practice guidelines","volume":"38","author":"Unger","year":"2020","journal-title":"J Hypertens"},{"key":"10.1016\/j.ahj.2023.05.019_bib0029","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.tcm.2019.03.002","article-title":"New approach to blood pressure control: Triple combination pill","volume":"30","author":"Volpe","year":"2020","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.ahj.2023.05.019_bib0030","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1161\/01.HYP.0000254479.66645.a3","article-title":"Low-dose quadruple antihypertensive combination: more efficacious than individual agents\u2013a preliminary report","volume":"49","author":"Mahmud","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2023.05.019_bib0031","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S0140-6736(17)30260-X","article-title":"Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review","volume":"389","author":"Chow","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2023.05.019_bib0032","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/jama.2018.10359","article-title":"Fixed low-dose triple combination antihypertensive medication vs usual care for blood pressure control in patients with mild to moderate hypertension in Sri Lanka: a randomized clinical trial","volume":"320","author":"Webster","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2023.05.019_bib0033","doi-asserted-by":"crossref","first-page":"5735","DOI":"10.2147\/DDDT.S286586","article-title":"Low-dose triple antihypertensive combination therapy in patients with hypertension: a randomized, double-blind, phase II study. drug design","volume":"14","author":"Hong","year":"2020","journal-title":"devel Ther"},{"key":"10.1016\/j.ahj.2023.05.019_bib0034","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0140-6736(21)01922-X","article-title":"Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial","volume":"398","author":"Chow","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2023.05.019_bib0035","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","article-title":"SPIRIT 2013 statement: defining standard protocol items for clinical trials","volume":"158","author":"Chan","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2023.05.019_bib0036","first-page":"209","article-title":"National Clinical Practice Guidelines on the Management of Hypertension in Primary Health Care in Chnia (2020)","volume":"36","year":"2021","journal-title":"Chinese Circulat J"},{"key":"10.1016\/j.ahj.2023.05.019_bib0037","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1136\/hrt.2010.221473","article-title":"How quickly should we titrate antihypertensive medication? Systematic review modelling blood pressure response from trial data","volume":"97","author":"Lasserson","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.ahj.2023.05.019_bib0038","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1097\/01.hjh.0000194120.42722.ac","article-title":"The felodipine event reduction (FEVER) study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients","volume":"23","author":"Liu","year":"2005","journal-title":"J Hypertens"},{"key":"10.1016\/j.ahj.2023.05.019_bib0039","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1161\/HYPERTENSIONAHA.111.189381","article-title":"A double-blind, placebo-controlled, crossover trial comparing the effects of amiloride and hydrochlorothiazide on glucose tolerance in patients with essential hypertension","volume":"59","author":"Stears","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2023.05.019_bib0040","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.3877","article-title":"Analysis of dual combination therapies used in treatment of hypertension in a multinational cohort","volume":"5","author":"Lu","year":"2022","journal-title":"JAMA Netw Open"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870323001424?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870323001424?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:59:00Z","timestamp":1762077540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870323001424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":40,"alternative-id":["S0002870323001424"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2023.05.019","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Initial treatment with a single capsule containing half-dose quadruple therapy vs standard-dose dual therapy in hypertensive patients (QUADUAL): Study protocol for a randomized, blinded, crossover trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2023.05.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}